Antidepressant Withdrawal and Rebound Phenomena.
Journal
Deutsches Arzteblatt international
ISSN: 1866-0452
Titre abrégé: Dtsch Arztebl Int
Pays: Germany
ID NLM: 101475967
Informations de publication
Date de publication:
17 May 2019
17 May 2019
Historique:
received:
31
10
2018
revised:
31
10
2018
accepted:
14
03
2019
entrez:
11
7
2019
pubmed:
11
7
2019
medline:
9
6
2020
Statut:
ppublish
Résumé
Antidepressants are among the most commonly prescribed drugs worldwide. They are often discontinued, frequently without the knowledge of the prescribing physician. It is, therefore, important for physicians to be aware of the withdrawal and rebound phenomena that may arise, in order to prevent these phenomena, treat them when necessary, and counsel patients appropriately. This review is based on a comprehensive, structured literature search on antidepressant withdrawal phenomena that we carried out in the CENTRAL, PubMed (Medline), and Embase databases. We classified the relevant publications and reports by their methodological quality. Out of a total of 2287 hits, there were 40 controlled trials, 38 cohort studies and retrospective analyses, and 271 case reports that met the inclusion criteria. Withdrawal manifestations are usually mild and self-limiting; common ones include dizziness, headache, sleep disturbances, and mood swings. More serious or pro- longed manifestations rarely arise. There is an increased risk with MAO inhibitors, tricyclic antidepressants, venlafaxine, and paroxetine; on the other hand, for agome- latine and fluoxetine, abrupt discontinuation seems to be unproblematic. There is also some evidence of rebound phenomena, i.e., of higher relapse rates or especially severe relapses of depression after the discontinuation of an anti- depressant. A robust evidence base now indicates that there can be acute with- drawal phenomena when antidepressants are discontinued. Putative rebound phenomena have not been adequately studied to date. It is recommended that antidepressants should be tapered off over a period of more than four weeks.
Sections du résumé
BACKGROUND
BACKGROUND
Antidepressants are among the most commonly prescribed drugs worldwide. They are often discontinued, frequently without the knowledge of the prescribing physician. It is, therefore, important for physicians to be aware of the withdrawal and rebound phenomena that may arise, in order to prevent these phenomena, treat them when necessary, and counsel patients appropriately.
METHODS
METHODS
This review is based on a comprehensive, structured literature search on antidepressant withdrawal phenomena that we carried out in the CENTRAL, PubMed (Medline), and Embase databases. We classified the relevant publications and reports by their methodological quality.
RESULTS
RESULTS
Out of a total of 2287 hits, there were 40 controlled trials, 38 cohort studies and retrospective analyses, and 271 case reports that met the inclusion criteria. Withdrawal manifestations are usually mild and self-limiting; common ones include dizziness, headache, sleep disturbances, and mood swings. More serious or pro- longed manifestations rarely arise. There is an increased risk with MAO inhibitors, tricyclic antidepressants, venlafaxine, and paroxetine; on the other hand, for agome- latine and fluoxetine, abrupt discontinuation seems to be unproblematic. There is also some evidence of rebound phenomena, i.e., of higher relapse rates or especially severe relapses of depression after the discontinuation of an anti- depressant.
CONCLUSION
CONCLUSIONS
A robust evidence base now indicates that there can be acute with- drawal phenomena when antidepressants are discontinued. Putative rebound phenomena have not been adequately studied to date. It is recommended that antidepressants should be tapered off over a period of more than four weeks.
Identifiants
pubmed: 31288917
pii: arztebl.2019.0355
doi: 10.3238/arztebl.2019.0355
pmc: PMC6637660
doi:
pii:
Substances chimiques
Antidepressive Agents
0
Serotonin Uptake Inhibitors
0
Fluoxetine
01K63SUP8D
Paroxetine
41VRH5220H
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
355-361Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Am J Psychiatry. 1999 Apr;156(4):661-2
pubmed: 10200756
J Clin Psychiatry. 1999 Aug;60(8):563-7; quiz 568-9
pubmed: 10485646
Psychoneuroendocrinology. 2000 Feb;25(2):169-77
pubmed: 10674280
Br J Psychiatry. 1999 Oct;175:390
pubmed: 10789310
Int Clin Psychopharmacol. 2000 Nov;15(6):305-18
pubmed: 11110006
Int Clin Psychopharmacol. 2000 Nov;15(6):329-33
pubmed: 11110008
Eur Neuropsychopharmacol. 2002 Feb;12(1):81-7
pubmed: 11788245
CNS Drugs. 2002;16(4):273-83
pubmed: 11945110
Psychother Psychosom. 2002 Jul-Aug;71(4):195-9
pubmed: 12097784
J Neurosci. 2002 Aug 1;22(15):6766-72
pubmed: 12151556
Int Clin Psychopharmacol. 2002 Sep;17(5):217-25
pubmed: 12177584
Pharmacotherapy. 2003 May;23(5):678-81
pubmed: 12741444
Biol Psychiatry. 2003 Sep 1;54(5):534-9
pubmed: 12946882
Am J Psychiatry. 1961 Dec;118:549-50
pubmed: 14459296
Eur Psychiatry. 2003 Dec;18(8):384-93
pubmed: 14680714
Biol Psychiatry. 2004 Feb 1;55(3):313-6
pubmed: 14744474
Prim Care Companion J Clin Psychiatry. 2002 Apr;4(2):78
pubmed: 15014751
Neuropsychobiology. 2004;50(1):57-64
pubmed: 15179022
Int Clin Psychopharmacol. 2004 Sep;19(5):271-80
pubmed: 15289700
Hum Psychopharmacol. 2004 Dec;19(8):585-6
pubmed: 15570574
N Engl J Med. 2005 Mar 17;352(11):1112-20
pubmed: 15784664
J Clin Psychiatry. 2005 Oct;66(10):1270-8
pubmed: 16259540
J Clin Psychiatry. 2005 Oct;66(10):1312-20
pubmed: 16259546
J Affect Disord. 2005 Dec;89(1-3):207-12
pubmed: 16266753
Int J Neuropsychopharmacol. 2006 Oct;9(5):495-505
pubmed: 16316482
Int J Neuropsychopharmacol. 2007 Feb;10(1):73-84
pubmed: 16359583
Can J Clin Pharmacol. 2006 Winter;13(1):e69-74
pubmed: 16456219
Int Clin Psychopharmacol. 2006 May;21(3):159-69
pubmed: 16528138
J Psychiatr Res. 2006 Jun;40(4):328-36
pubmed: 16678205
Int Clin Psychopharmacol. 2006 Sep;21(5):297-309
pubmed: 16877901
Int J Neuropsychopharmacol. 2007 Dec;10(6):835-8
pubmed: 17224089
Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66
pubmed: 17335951
Int Clin Psychopharmacol. 2007 May;22(3):167-74
pubmed: 17414743
Arch Gen Psychiatry. 2007 Aug;64(8):903-12
pubmed: 17679635
PLoS Med. 2008 Feb;5(2):e45
pubmed: 18303940
J Psychopharmacol. 2008 May;22(3):330-2
pubmed: 18515448
Am J Psychiatry. 1991 Sep;148(9):1263
pubmed: 1883010
J Clin Psychiatry. 2009 Aug;70(8):1128-37
pubmed: 19689920
Eur J Pharmacol. 2010 Mar 10;629(1-3):63-7
pubmed: 20006597
JAMA. 2010 Jan 6;303(1):47-53
pubmed: 20051569
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1593-602
pubmed: 20728491
Nat Rev Neurosci. 2011 Jun 02;12(7):400-13
pubmed: 21633380
Front Psychol. 2011 Jul 07;2:159
pubmed: 21779273
J Pharmacol Exp Ther. 2011 Nov;339(2):324-8
pubmed: 21849624
Med Hypotheses. 2011 Dec;77(6):1006-8
pubmed: 21920673
CNS Drugs. 2012 Feb 1;26(2):97-109
pubmed: 22296314
Curr Med Res Opin. 2012 May;28(5):815-21
pubmed: 22429066
J Clin Psychiatry. 2012 Jul;73(7):1002-8
pubmed: 22901350
Psychother Psychosom. 2012;81(6):386-8
pubmed: 22964821
Pharmacopsychiatry. 2013 Jun;46(4):123-9
pubmed: 23359339
J Clin Psychopharmacol. 2014 Jun;34(3):365-8
pubmed: 24717247
Int J Psychiatry Clin Pract. 2004;8(2):127-9
pubmed: 24926846
PLoS One. 2014 Jun 17;9(6):e99873
pubmed: 24937739
Psychother Psychosom. 2014;83(4):247-8
pubmed: 24968739
Hum Psychopharmacol. 2014 Nov;29(6):503-16
pubmed: 25111000
PLoS One. 2014 Sep 26;9(9):e106871
pubmed: 25259889
Psychother Psychosom. 2015 Feb 21;84(2):63-71
pubmed: 25721565
Psychother Psychosom. 2015 Feb 21;84(2):72-81
pubmed: 25721705
Prim Care Companion CNS Disord. 2015 Feb 05;17(1):null
pubmed: 26137358
Am J Drug Alcohol Abuse. 1989;15(3):345-50
pubmed: 2763988
Pharmacopsychiatry. 2018 Jan;51(1-02):9-62
pubmed: 28910830
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
Riv Psichiatr. 2018 Mar-Apr;53(2):95-99
pubmed: 29674777
Psychother Psychosom. 2018;87(5):268-275
pubmed: 30041180
Addict Behav. 2019 Oct;97:111-121
pubmed: 30292574
Addict Biol. 2019 Mar 21;:null
pubmed: 30896084
Hillside J Clin Psychiatry. 1985;7(1):16-33
pubmed: 3894196
J Clin Psychopharmacol. 1985 Dec;5(6):340-2
pubmed: 4067000
Am J Psychiatry. 1973 Nov;130(11):1286-7
pubmed: 4795181
Br Heart J. 1972 Oct;34(10):1042-4
pubmed: 5086971
Hypertension. 1984 Sep-Oct;6(5 Pt 2):II71-5
pubmed: 6150002
J Affect Disord. 1984 Feb;6(1):1-7
pubmed: 6231324
Biol Psychiatry. 1984 Feb;19(2):237-56
pubmed: 6324897
Br J Psychiatry. 1982 Oct;141:377-86
pubmed: 6756531
Br Med J (Clin Res Ed). 1981 Aug 1;283(6287):346
pubmed: 6788320
Am J Psychiatry. 1983 Feb;140(2):249-51
pubmed: 6849449
Am J Psychiatry. 1981 Jan;138(1):87-9
pubmed: 7446789
Lancet. 1995 Jul 1;346(8966):57
pubmed: 7603169
J Clin Psychiatry. 1994 Dec;55(12):544-5
pubmed: 7814353
S Afr Med J. 1994 Jan;84(1):5-6
pubmed: 7910983
Eur Arch Psychiatry Clin Neurosci. 1994;244(2):65-72
pubmed: 7948056
J Clin Psychopharmacol. 1994 Jun;14(3):206-7
pubmed: 8027419
J Clin Psychopharmacol. 1993 Jun;13(3):224-5
pubmed: 8354742
Pharmacotherapy. 1996 Jul-Aug;16(4):684-6
pubmed: 8840377
J Clin Psychopharmacol. 1996 Oct;16(5):356-62
pubmed: 8889907
Br J Psychiatry. 1997 Feb;170:120-7
pubmed: 9093499
Am Fam Physician. 1997 Aug;56(2):455-62
pubmed: 9262526
Harv Rev Psychiatry. 1998 Mar-Apr;5(6):293-306
pubmed: 9559348
J Clin Psychopharmacol. 1998 Jun;18(3):193-7
pubmed: 9617977
J Clin Psychiatry. 1998 May;59(5):255
pubmed: 9632038
Biol Psychiatry. 1998 Jul 15;44(2):77-87
pubmed: 9646889
Am J Psychiatry. 1998 Oct;155(10):1443-5
pubmed: 9766780
Psychopharmacology (Berl). 1998 Dec;140(4):470-7
pubmed: 9888623